



Vaccines and Global Health: The Week in Review
15 February 2025 :: Issue 786
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

:: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

"Pandemic Accord"

Thirteenth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response

17 – 21 February 2025

Webcast: 09:00–12:30, 14:00–17:30 CET, Geneva, Switzerland

In December 2021, the World Health Assembly established an Intergovernmental Negotiating Body (INB) to draft and negotiate a convention, agreement or other international instrument under the Constitution of the World Health Organization, to strengthen pandemic prevention, preparedness and response.

The thirteenth meeting of the INB is to be held in hybrid format from 17–21 February 2025. The opening and closing plenary sessions of the INB are open to WHO Member States, Associate Members, Observers and regional economic integration organizations, as well all relevant stakeholders. These sessions, on 17 and 21 February, will be publicly webcast and archived for later viewing. Relevant stakeholders (Annexes A–E) will be invited to join for a brief open session at the beginning of each day to be updated on progress and provide their views on relevant Articles. Substantive negotiating sessions will be held in closed format.

.....
.....

WHO Executive Board

156th session of the Executive Board

3–11 February 2025

The Executive Board is composed of 34 technically qualified members elected for three-year terms. The main functions of the Board are to implement the decisions and policies of the Health Assembly, and to advise and generally facilitate its work.

Main Documents

Agenda and Supporting Reports, Documents; Watch recorded Executive Board sessions [here](#)

Speeches

11 February 2025

WHO Director-General's closing remarks at the 156th session of the Executive Board – 11 February 2025

[Excerpt]

...I thank all Member States, members and non-members of the board, and non-state actors and UN organizations, for your engagement in this meeting, and your support for the success of our WHO. You have dealt with a very significant agenda – both in terms of its size and its importance.

Thank you in particular for your decision to recommend the Programme Budget 2026-27 to the World Health Assembly;

And thank you for the confidence you have shown by recommending the 20% increase in assessed contributions, and for honouring the commitment you made in 2022 to increase assessed contributions to 50% of the base budget.

This is a very strong signal of your support; And it is a major step towards putting WHO on a more predictable and sustainable financial footing...

.....
.....

WHO Director-General's opening remarks at the media briefing – 12 February 2025

[Excerpt]

===

A significant part of WHO's response to health emergencies in Uganda, DRC, Gaza, Sudan and elsewhere is supported by funding from the United States.

As we have said, we regret the announcement that the United States intends to withdraw from WHO, and we would welcome the opportunity to engage in constructive dialogue.

There are also actions that the U.S. government is taking that are unrelated to its intended withdrawal from WHO, but which we are concerned are having a serious impact on global health.

For example, the suspension of funding to PEPFAR, the President's Emergency Plan for AIDS Relief, caused an immediate stop to HIV treatment, testing and prevention services in the 50 countries that PEPFAR supports, based on bilateral agreements.

Although a waiver has been granted for life-saving services, it does not include prevention services for some of the most at-risk groups.

Despite the waiver, clinics are shuttered and health workers have been put on leave.

WHO is gathering data on service disruptions and supporting countries with mitigation measures, including by filling gaps in supplies of antiretrovirals.

The sudden suspension of U.S. funding and the sudden disengagement of US institutions is also affecting the response to global efforts to eradicate polio, and the response to mpox epidemics in Africa;

In Myanmar, almost 60 000 people, most of them women and children, have been left with no access to life-saving services;

And we have limited information about the spread of avian influenza among dairy cattle in the U.S., or human cases.

We ask the U.S. to consider continuing its funding, at least until solutions can be found.

===

.....
.....

U.S. Actions – U.S./Global Health

Editor's Note:

We continue to track the Trump Administration's numerous Executive Orders and their resulting implementation with special attention to those which impact public health in the U.S. and globally. The

Fact Sheet below was issued in parallel with an [Executive Order](#) focused on the same issue. We are actively drafting an expression of concern which will be posted shortly.

Fact Sheet: President Donald J. Trump Prohibits Federal Funding for COVID-19 Vaccine Mandates in Schools

February 14, 2025

PROHIBITING COVID-19 VACCINE MANDATES IN SCHOOLS:

Today, President Donald J. Trump signed an [Executive Order](#) to prohibit federal funding for COVID-19 vaccine mandates in schools.

- The Order bars federal funds from being used to support or subsidize an educational service agency, state education agency, local education agency, elementary school, secondary school, or institution of higher education that requires students to have received a COVID-19 vaccination to attend in-person education programs.
- The Secretary of Education and the Secretary of Health and Human Services must issue guidelines for compliance and provide a plan to end coercive COVID-19 vaccine mandates, including a report on non-compliant entities and a process for preventing federal funds from supporting educational entities that impose COVID-19 vaccine mandates.

PUTTING AN END TO GOVERNMENT OVERREACH:

President Trump is committed to protecting personal freedoms and ensuring that Americans' education isn't conditioned on unnecessary government mandates.

- Some schools and universities have recently enforced or continue to enforce COVID-19 vaccine mandates, making access to education contingent upon students' COVID-19 vaccination status.
- These mandates pressure students into making COVID-19 vaccine decisions based on government coercion, rather than on their own informed choices.
- Studies consistently show that children and young adults have an incredibly low risk of developing a severe illness from COVID-19.
- With COVID-19 vaccine mandates threatening educational opportunities for students, parents are being forced into a difficult position: comply with a controversial mandate or risk their child's educational future.

PROMISES MADE, PROMISES KEPT:

- President Trump is dedicated to ensuring that American students are not forced to choose between their education and their medical freedom.
- President Trump is fulfilling his campaign promise: "I will not allow schools to impose COVID vaccine mandates..."
- In President Trump's first week in office, he reinstated service members who were dismissed for refusing the COVID vaccine, with full back pay and benefits.
- President Trump is as a staunch advocate for parental rights, ensuring families have the primary role in shaping their children's educational journey, free from undue bureaucratic mandates.

.....
.....

Immunization – Humanitarian/Conflict Settings

9 million vaccine doses administered to children living in humanitarian settings in the Horn of Africa

- Gavi and IRC's REACH consortium administered 9 million vaccine doses, protecting against diseases such as measles and diphtheria
- Consortium negotiates access to reach 96% of communities in hard-to-reach areas across the region

- Conflict, displacement and climate-driven droughts continue to hinder health access and control of vaccine-preventable diseases in the region

Geneva / Addis Ababa, 13 February 2025 – **The Reaching Every Child in Humanitarian Settings (REACH) consortium** has officially administered 9 million vaccine doses to children in humanitarian and conflict-affected regions across the Horn of Africa.

REACH is funded by Gavi, the Vaccine Alliance (Gavi) and led by the International Rescue Committee (IRC), in collaboration with ThinkPlace, Flowminder, CORE Group and a broad array of local civil society organizations.

21 million children around the world, particularly in fragile settings, remain under-immunized, with 14.5 million having never received a single dose of any vaccine. Reaching these under-served communities with immunization is critical to preventing outbreaks that threaten both regional and global health security.

To serve communities in crisis – some of which haven't seen a vaccine in over a decade – Gavi launched the Zero-Dose Immunization Programme (ZIP) in 2022, partnering directly with humanitarian organizations. As part of this programme, **REACH relies on a specialized humanitarian model addressing complex barriers, leveraging the IRC's humanitarian expertise**, which has proven essential in ensuring that even the hardest-to-reach children receive the full national schedule of vaccines.

When REACH launched in 2022, only 16% of the 156 target communities were accessible to humanitarian actors. **Centring humanitarian principles, the consortium has now negotiated access to 96%.** Through flexible and adaptable delivery models, such as mobile clinics and community outreach units, hyperlocal partners and geospatial mapping, REACH is enabling immunization in regions where existing government health systems cannot function due to insecurity, conflict or crises, including those driven by climate change. By closely coordinating with the Ministry of Health (MoH) and the national immunization programme (NIP), REACH transitions services back to government ownership when conditions allow...

David Miliband, President and CEO of the IRC, said: "The success of the REACH consortium is measured not only in lives saved and communities reached, but also in the critical boost to global health security interventions like these provide. It is inspiring to meet the children whose life chances improve each time they receive a vaccine from the consortium. **It is astonishing to think REACH and its partners have done these 9 million times over. This is a prime example of what is possible when the best of immunization, the best of innovation and the best of humanitarian expertise come together.** This breakthrough model cannot be allowed to wither on the vine."...

Beyond the scale of vaccine doses delivered in the region, **REACH is ensuring that more children achieve full immunization across the Horn of Africa, including older children who have missed their routine immunization schedules.** To date, over 985,000 children aged 0–5 years have received the first dose of diphtheria, tetanus and pertussis-containing vaccine (DTP1), setting them on a pathway to complete their immunization schedule. Of those, 376,000 children received DTP1 past their first birthday, which demonstrates that progress is being made in reaching those who missed out on routine vaccination programmes earlier in their childhood.

.....
.....

AMR

Philanthropic Partnership Launches New Initiative Tackling Antimicrobial Resistance, the Third-Leading Cause of Death Globally, By Fast-Tracking Discovery of New Treatments

Initiative marks first investment of global health partnership between the Gates Foundation, Novo Nordisk Foundation, and Wellcome to address global health challenges that disproportionately impact people living in low- and middle-income countries

Press release

SEATTLE, COPENHAGEN, LONDON (February 12, 2025) – **The Gates Foundation, Novo Nordisk Foundation, and Wellcome today announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a \$50 million investment that will focus on combatting antimicrobial resistance (AMR) caused by a specific range of bacteria that are among the leading contributors to AMR-associated deaths.**

The Gr-ADI will function as a consortium where multiple funders, research institutions, and industry partners share data and work collectively to drive innovation in the discovery of urgently needed new drugs.

The Gr-ADI is the first investment of the \$300 million global health research and development partnership launched by these three philanthropic organizations last year.

The broader partnership will support science and innovation to advance solutions to health challenges that disproportionately impact people in low- and middle-income countries (LMICs), including climate and sustainability; infectious diseases; and the interplay between nutrition, immunity, infectious diseases, cardiometabolic and other noncommunicable diseases and developmental outcomes...

Projects funded through the Gr-ADI will be selected by the partners through a request for proposals (RFP) that leverages the Gates Foundation's Grand Challenges platform, an initiative that has fostered innovation to solve key global health and development problems for more than 20 years.

The focus of this RFP will be on the discovery of antibiotics with broad spectrum activity against Enterobacteriaceae, the Gram-negative family of bacteria that includes *Klebsiella spp.*, which is the pathogen that should be used in proposed projects. Enterobacteriaceae are included on the World Health Organization's list of critical priority pathogens and are among the leading contributors to global AMR-associated deaths, disproportionately impacting people living in low- and middle-income countries where the drivers of AMR are exacerbated by poverty and inequality.

"New drugs are critical to preventing needless deaths from the superbugs created by AMR," said Trevor Mundel, president of global health at the Gates Foundation. "An unconventional model of drug discovery and development—driven by innovative approaches and cross-organization collaboration—could be the key to unlocking the pipeline of antibiotics that can be used to target drug-resistant pathogens. We've seen this work incredibly well in other areas, like tuberculosis (TB) drug development, and I have confidence that this is the right approach for combatting bacterial AMR."

The call for proposals will close on March 25, 2025. Researchers, particularly from countries where AMR poses a serious threat, are encouraged to submit a proposal for the Gram-Negative Antibiotic Discovery Innovator [here](#).

:::::::
:::::::

[Multi-country outbreak of mpox, WHO External situation report #47 - 13 February 2025](#)

Highlights

- **The outbreak of mpox due to clade Ib monkeypox virus (MPXV) continues predominantly in the Democratic Republic of the Congo, Burundi and Uganda**, with new travel-related cases identified in previously unaffected countries.
- In the last six weeks, Uganda has reported the second-highest number of confirmed cases, which constitute over a third of all confirmed cases reported on the continent during this period, with ongoing increase in weekly incidence.²
- The Democratic Republic of the Congo continues to experience a high burden of mpox, with circulation of both clade I MPXV subclades. Despite many of the provinces reporting stable trends in cases, the situation in the country remains concerning, with many areas seeing sustained transmission. The escalating violence in the eastern part of the country poses additional challenges for the mpox response.
- New travel-related cases of mpox due to clade Ib MPXV have been detected in countries that had already detected travel-related cases before, including Thailand and the United Kingdom of Great Britain and Northern Ireland.
- The United Arab Emirates has reported its first detection of a case of mpox due to clade Ib MPXV in-country.

5. Access to and delivery of countermeasures – Access and Allocation Mechanism (AAM)

Vaccines

- WHO continues to provide technical support to accelerate implementation and uptake of mpox vaccination in affected countries in at-risk groups, in support of controlling the surge in mpox cases on the African continent.
- Following advocacy by WHO and partners, the Pharmaceutical Regulatory Authority of the Democratic Republic of the Congo updated its Emergency Use Authorization for mpox vaccines to include children one year and above on 17 January 2025.
- **During the first vaccine allocation round, nine countries were allocated vaccine doses and seven countries fully accepted their allocation (Côte d'Ivoire, Democratic Republic of the Congo, Rwanda, Kenya, Liberia, South Africa, and Uganda).** Efforts are underway to advance the delivery of remaining vaccine doses that were allocated during the first allocation round, to finalize the outstanding shipment arrangements and documentation.
- **During the second round, four countries (Angola, Guinea, Sierra Leone and Uganda) were allocated a total of 238 300 vaccine doses.** A total of 470 000 doses of MVA-BN vaccine remain available for allocation after the second allocation round (1400 doses from Croatia, 500 doses from Cyprus, 33 000 doses from France, and 435 000 doses from UNICEF), as well as 3 million doses of LC16m8 vaccine from Japan and 50 000 doses of ACAM2000 vaccine from Emergent BioSolutions.
- To date, 516 480 vaccines have been delivered to six countries, including 50 000 doses of LC16m8 vaccine from Japan to the Democratic Republic of the Congo in January 2025. Vaccination had been reported to have started in four countries (Central African Republic, Democratic Republic of the Congo, Nigeria, and Rwanda) by the publication of this report.
- The AAM partners continue to work together to ensure countries receive guidance to get operational funds for implementation of the national vaccination plans.

.....

Featured Journal Content

Lancet Infectious Diseases

Vaccination in Africa—no hesitancy without access

The Lancet Infectious Diseases

Mpox vaccines are finally trickling into Africa after having been available in non-endemic, high-income countries for more than 2 years. Yet, they will have limited impact in stemming the ongoing outbreaks of monkeypox virus on the continent if people refuse them. An [online survey](#) of 1832 adults in six African countries, published in *eClinicalMedicine*, reported with high heterogeneity that 32·7% of respondents would be hesitant to receive an mpox vaccine, and 38·9% of parents would be hesitant to have their children vaccinated. Along similar lines, a [systematic review and meta-analysis](#) published last year described how, of six WHO regions, the African region had the lowest level of mpox vaccine acceptance of 41·9%. These data are consistent with a larger body of evidence indicating a concerning high prevalence of vaccine hesitancy in Africa.

WHO defines vaccine hesitancy as a delay or refusal of vaccines despite the availability of vaccination services. It is not a new concept, nor is it unique to Africa, but it is context-specific, varying across geographies, between and within populations, and over time. In the context of Africa, scarce research was done on vaccine hesitancy before the COVID-19 pandemic, so not much is understood about hesitancy towards vaccines other than those for COVID-19. Many determinants of vaccine hesitancy in Africa have also been described elsewhere, although sometimes with different magnitudes and directions of association. These include socioeconomic, religious, and cultural factors, as well as health literacy. Concerns about vaccine safety are commonly cited, as well as skepticism about the motivations of foreign vaccine manufacturers—for instance, believing that they intend harm or, as witnessed historically, are using Africa as a testing ground for potentially unsafe products that will ultimately benefit non-Africans. Mistrust in medical institutions and governments—especially prevalent in groups that have been historically marginalised, that have been exploited in the name of so-called scientific advancement, or who live in countries where political corruption is rife—also influences attitudes towards vaccination. As seen elsewhere, deep-rooted mistrust in those responsible for or implementing vaccination programmes can increase how receptive people are to misinformation and conspiracy theories spread on social media.

How can trust be built in this context? Removing foreign involvement might help. Respondents to a [qualitative study](#) in South Africa in August 2020 indicated that the performance of COVID-19 vaccine trials locally would influence their decision to be vaccinated. Similarly, Africans may be more accepting of a vaccine originating from Africa—an increasing possibility due to rising vaccine manufacturing capacity on the continent.

Digital interventions might prove useful to simultaneously dispel misinformation and increase health literacy. One such example includes a [pre-post evaluation](#) of the One by One: Target COVID-19 campaign in Tanzania, which used trained, high-profile, trusted influencers on social media to deliver key messages about COVID-19 vaccination. The study found some positive associations with COVID-19 vaccine confidence, hesitancy, and uptake, although the impact differed according to age group. Nonetheless, a reliance on digital interventions risks missing groups without access to digital technologies, and so alternative approaches are needed. Noteworthy is a study in a hard-to-reach fishing community in Cameroon that used an integrated health-care package delivered by community health workers to address the complex health needs of the population. In doing so, the investigators were able to build trust and saw increases in childhood immunisation uptake. Importantly, the intervention was designed and implemented with input from the community, a prerequisite for an effective intervention.

Vaccine hesitancy in Africa is concerning and an important threat to global health. However, to what extent does it contribute to low immunisation coverage compared with, say, access or structural barriers? The multicountry survey of mpox vaccine hesitancy found that absence of immunisation coverage for other vaccines was associated with an increased risk of mpox vaccine hesitancy, perhaps indicating that issues of hesitancy and access are interconnected. It is true that vaccine hesitancy needs to be addressed in order to reduce the burden of vaccine-preventable diseases in Africa, but—per the WHO definition—hesitancy can exist only when vaccines are available.

.....

Polio – PHEIC

Polio this week – 05 February 2025

Headlines

:: WHO Executive Board says emergency measures needed to stop polio

Global polio and health experts urge right geopolitical decisions to stop 'perfect storm' for poliovirus transmission and protect eradication

07/02/2025

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: 23 WPV1-positive environmental samples

.....

.....

Public Consultations/Call for Inputs/Call for Papers

E6(R3) Good Clinical Practice: Annex 2; International Council for Harmonisation; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 12/30/2024 **Comment period ends 02/28/2025**

SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "E6(R3) Good Clinical Practice: Annex 2." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is the second annex to "E6(R3) Good Clinical Practice" published June of 2023. This annex provides additional considerations for the application of good clinical practices to a variety of trial designs and data sources. Specifically, this draft guidance discusses trials with decentralized and pragmatic elements and real-world data sources. This draft guidance highlights the importance of quality by design and focusing efforts and resources on critical aspects of the trials that might impact the safety of participants and the reliability of results. The draft guidance is intended to encourage innovation in trial design and provides flexible, modern, and clear good clinical practices for conducting trials, while avoiding unnecessary complexities.

.....

.....

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

.....
.....

WHO & Regional Offices [to 15 Feb 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

No new digest content identified.

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 11 February 2025

[Angola vaccinates over 1 million people as it bolsters cholera outbreak control efforts](#)

WHO Region of the Americas PAHO

:: 14 Feb 2025

[New PAHO guide aims to improve early detection and survival rates of childhood cancer in Latin America and the Caribbean](#)

Washington, D.C., February 14, 2025 (PAHO) — On the occasion of International Childhood Cancer Day, observed every February 15, the Pan American Health Organization (PAHO) has launched a new interactive guide aimed at improving the early diagnosis of childhood cancer, one of the leading causes of death among children and adolescents in Latin...

11 Feb 2025

[WHO, St. Jude, PAHO launch groundbreaking international delivery of childhood cancer medicines](#)

Ecuador will be among the first countries to receive a shipment

11 February 2025, Geneva / Memphis -- The World Health Organization (WHO) and St. Jude Children's Research Hospital have commenced distribution of critically-needed childhood cancer medicines in 2 of 6 pilot countries, through the Global Platform for Access to Childhood Cancer...

10 Feb 2025

[PAHO warns of increased risk of dengue outbreaks due to circulation of DENV-3 in the Americas](#)

Washington, D.C., February 10, 2025 (PAHO) – The Pan American Health Organization (PAHO) has issued an epidemiological alert regarding the increased risk of dengue outbreaks in the Americas, attributed to the growing circulation of the DENV-3 serotype in several countries in the region. PAHO urges countries to strengthen their surveillance, early...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 10 February 2025 *Media release*

[Dr Hans Henri P. Kluge reappointed as WHO Regional Director for Europe](#)

WHO Eastern Mediterranean Region EMRO

:: [Oman introduces a new laboratory to boost testing for poliovirus in the Region](#)

13 February 2025

:: [The struggle to access cancer care in Afghanistan](#)

11 February 2025

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

[Multi-country outbreak of mpox, External situation report #47 - 13 February 2025](#)

[WHO's Operational Update on Health Emergencies - December 2024](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[14 February 2025 | Marburg Virus Disease–United Republic of Tanzania](#)

Situation at a glance

Since the declaration of the Marburg Virus Disease (MVD) outbreak on 20 January 2025 in the United Republic of Tanzania, one additional confirmed death was reported by the Ministry of Health from the epicentre of the outbreak in Biharamulo district in Kagera region. As of 10 February 2025, a cumulative of two confirmed and eight probable cases were reported by the Ministry of Health. All 10 cases have died, including eight who died before the confirmation of the outbreak. As of 10 February 2025, all 281 contacts that were listed and under monitoring have completed the 21-day follow-up. The Ministry of Health developed a national response plan to guide activities. Additionally, a national rapid response team was deployed to the affected region to enhance outbreak investigation and response, with technical and operational support from WHO and health partners...

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 100, Nos. 07/08, pp. 45–60 14 February 2025

PDF: <https://iris.who.int/bitstream/handle/10665/380483/WER10007-08-eng-fre.pdf>

:: Two decades of influenza surveillance in North Africa

.....

New WHO Publications

<https://www.who.int/publications>

Selected

13 February 2025

[Mekong Malaria Elimination Programme epidemiology summary, volume 27, July–September 2024](#)

12 February 2025

[Roadmap for research on maternal and perinatal health in the context of epidemic threats](#)

Overview

This Roadmap represents a significant milestone in the global pursuit of enhanced maternal and perinatal health during epidemics and pandemics. It describes collaborative means to address the most

pressing challenges that hinder the generation of high-quality evidence on the direct and indirect effects of epidemics on maternal and perinatal health.

11 February 2025

[WHO global framework to define and guide studies into the origins of emerging and re-emerging pathogens...](#)

Overview

The WHO global framework to define and guide studies into the origins of emerging and re-emerging pathogens with epidemic and pandemic potential, developed by the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) has been designed as a resource for Member States. It provides, for the first time, comprehensive guidance on the studies that are needed to investigate the origins of emerging and reemerging pathogens...

.....
.....

USA – HHS, FDA, CDC

HHS

News

[Robert F. Kennedy, Jr. Sworn in as 26th Secretary at HHS, President Trump Signs Executive Order to Make America Healthy Again](#)

February 13, 2025 *News Release*

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

No new VRBPAC calendar dates identified.

CDC/ACIP [U.S.] [to 15 Feb 2025]

<http://www.cdc.gov/media/index.html>

Latest News

Last news release 10 Jan 2025.

ACIP Meetings [to 15 Feb 2025]

Next ACIP Meeting

February 26-27, 2025

[Agenda for February 26-28](#) ***[Appears stable from earlier agenda versions]***

National Vaccine Program

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

MMWR Weekly

<https://www.cdc.gov/mmwr/index2024.html>

The January 16th MMWR [below] which we carried in an earlier edition no longer appears on the MMWR webpage. We note the two ACIP recommended immunization schedules that comprise this edition. The PDF link below is still active.

MMWR Weekly, January 16, 2025 / No. 2

[PDF of this issue](#)

- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025](#)
- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025](#)

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

No new digest content identified.

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

[Communicable disease threats report, 8 - 14 February 2025, week 7](#)

14 Feb 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 February and includes updates on STI cases, chikungunya, Ebola, measles, avian influenza A (H9N2, H5N1), swine influenza A(H1N2), influenza (H10N3) and an overview of respiratory virus epidemiology in the EU/EEA.

Surveillance and monitoring

[Gonorrhoea - Annual Epidemiological Report for 2023](#)

10 Feb 2025

For 2023, 96 969 confirmed cases of gonorrhoea were reported in 28 European Union/European Economic Area (EU/EEA) countries, with a crude notification rate of 25.0 cases per 100 000 population, representing a 31% increase in the crude notification rate compared with 2022.

.....
.....

Africa CDC [to 15 Feb 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Statement

[Africa CDC Director-General, Dr. Jean Kaseya, Receives Prestigious Award from African Union Chairperson](#)

Addis Ababa, February 15, 2025 – Africa CDC proudly celebrates the recognition of our Director-General, H.E. Dr. Jean Kaseya, who has been honored with a prestigious award from outgoing AU Chairperson, H.E. President Mohamed Ould Ghazouani.

In his remarks, President Ghazouani stated, "For being the champion of health in Africa and for the excellent work you do in safeguarding the health of Africans, I hereby decorate you as Grand Officer of the Mauritanian Order."...

Stories

\$1.6m Allocated to Nine National Public Health Institutes Centers of Excellence

13 February 2025

... The selection of institutes in Ethiopia, Burkina Faso, Burundi, the Democratic Republic of Congo, Liberia, Mozambique, Nigeria, South Africa and Rwanda follows a rigorous assessment of NPHIs across Africa and aligns with Africa CDC's mission to enhance disease control policies and strengthen public health capacities in Member States. The agency has allocated \$1.6million for equipment and training to the Centres across the continent...

Stories

Plan to End Cervical Cancer in Africa by 2030

11 February 2025

Researchers led by the Africa Centers for Disease Control (Africa CDC) will establish three Centers of Excellence in Rwanda, Morocco, and Zambia to gather evidence and accelerate efforts to end cervical cancer in Africa by 2030. This decision was made during a consultative meeting on cervical cancer elimination, held from November 27-29 in Addis Ababa, with technical partners, donors, academia, and civil society organizations in attendance...

.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 15 Feb 2025]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 15 Feb 2025]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-02-14 / No. 7

[View PDF of this issue](#)

- [Vital Surveillances: Comparative Analysis of Epidemiological and Clinical Characteristics Between Mpox Cases with and Without HIV — China, 2023](#)
- [Vital Surveillances: Epidemiological Characteristics of Human Respiratory Syncytial Virus in Children with Acute Respiratory Infection — Shijiazhuang City, Hebei Province, China, 2021–2023](#)
- [Vital Surveillances: Variations in Prevalence and Characteristics of Rotavirus Diarrhea Among Outpatients — Shanghai Municipality, China, 2017–2023](#)
- [Outbreak Reports: An Imported Yellow Fever Adverse Events Following Immunization Case Identified by Targeted Next-Generation Sequencing — Guangdong Province, China, October 2024](#)

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)
:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 15 Feb 2025]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 15 Feb 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

Press release Feb 12, 2025

[Philanthropic Partnership Launches New Initiative Tackling Antimicrobial Resistance, the Third-Leading Cause of Death Globally, By Fast-Tracking Discovery of New Treatments](#)

Initiative marks first investment of global health partnership between the Gates Foundation, Novo Nordisk Foundation, and Wellcome to address global health challenges that disproportionately impact people living in low- and middle-income countries

Bill & Melinda Gates Medical Research Institute [to 15 Feb 2025]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 15 Feb 2025]

<https://carb-x.org/>

News

02.11.2025 |

[CARB-X funds Pearl to assess detection of bacterial pneumonia via urine sample](#)

CARB-X will award biotechnology Pearl Diagnostics US\$1.M to develop a low-cost, low turnaround time urine assay for the detection of pneumonia caused by *Pseudomonas aeruginosa*.

Chan Zuckerberg Initiative [to 15 Feb 2025]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 15 Feb 2025]

<http://cepi.net/>

CEPI News, Blog

News

[CEPI partners with Ethris to increase access to RNA vaccines through spray-dry technique](#)

10 Feb 2025

Blog

[Accessing innovation: Aurélia Nguyen's drive for science to benefit all](#)

10 Feb 2025

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 15 Feb 2025]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 15 Feb 2025]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [to 15 Feb 2025]

<https://dndi.org/press/press-releases/>

Press Releases

[DNDi announces organizational strategy update and strengthened executive team To boost medical innovation, equitable health access, and open science for neglected populations in an unstable world](#)

Geneva, Switzerland — 13 Feb 2025

Duke Global Health Innovation Center [to 15 Feb 2025]

<https://dukeghic.org/>

News

[Issue 7: 10 February 2025 | Mpox: Transparency and Accountability for the Global Response](#)

February 10, 2025

EDCTP [to 15 Feb 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

No new digest content identified.

Emory Vaccine Center [to 15 Feb 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 15 Feb 2025]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Fondation Merieux [to 15 Feb 2025]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 15 Feb 2025]

<https://www.gavi.org/>

Press Releases

14 February 2025

New deals announced to catalyse vaccine manufacturing in Africa

Cairo/Geneva 14 February 2025: The African Vaccine Manufacturing Accelerator (AVMA), launched in June 2024 to catalyse investment in Africa's vaccine manufacturing ecosystem, has already begun building confidence for groundbreaking partnerships, with two new collaborations signed last week in a positive step towards enhanced health security.

The collaborations, signed on the sidelines of the 2nd Vaccine and Other Health Products Manufacturing Forum in Cairo – co-hosted by Gavi, African Union (AU), Africa Centres for Disease Control and Prevention (Africa CDC), and the Arab Republic of Egypt – are:

- EVA Pharma (Egypt) announced a groundbreaking collaboration with DNA Script (France), Quantoom Biosciences (Belgium), and Unizima (Belgium) to establish the first digital-to-biologics end-to-end mRNA development and production platform in Africa...
- Biogeneric Pharma (Egypt) and Afrigen (South Africa) signed an addendum to their MoU focused on strengthening their partnership in developing mRNA platform technology...

13 February 2025

9 million vaccine doses administered to children living in humanitarian settings in the Horn of Africa

- Gavi and IRC's REACH consortium administered 9 million vaccine doses, protecting against diseases such as measles and diphtheria
- Consortium negotiates access to reach 96% of communities in hard-to-reach areas across the region
- Conflict, displacement and climate-driven droughts continue to hinder health access and control of vaccine-preventable diseases in the region

11 February 2025

Government of Canada and Gavi deliver 200,000 doses of donated mpox vaccine to DRC

GE2P2 Global Foundation [to 15 Feb 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – February 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 14 Jan 2025](#)

GHIT Fund [to 15 Feb 2025]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 15 Feb 2025]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 15 Feb 2025]

<https://www.glopid-r.org/news/>

News

[GloPID-R's work showcased in latest IPPS Report](#)

February 10, 2025

Hilleman Laboratories [to 15 Feb 2025]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 15 Feb 2025]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 15 Feb 2025]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 15 Feb 2025]

<https://www.iavi.org/>

Press Releases

No new digest content identified.

INSERM [to 15 Feb 2025]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 15 Feb 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 15 Feb 2025]

<https://www.icrc.org/en/whats-new>

Latest press releases and statements [Selected]

[Upholding the ceasefire in Gaza is an imperative for preserving human life and dignity](#)

Statement 12-02-2025

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 15 Feb 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

[Türkiye and Syria earthquakes two years on: A long road to recovery](#)

05/02/2025 | Press release

IPPS - International Pandemic Preparedness Secretariat [to 15 Feb 2025]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [to 15 Feb 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press release 12.02.2025

[Mpox: a better understanding of tecovirimat resistance](#)

A virus originally found in animals, mpox – which causes the disease of the same name – is now circulating in humans....

ISC / International Science Council [to 15 Feb 2025]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

19th International Congress of Immunology

Vienna, August 17-22, 2025.

IVAC [to 15 Feb 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 15 Feb 2025]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 15 Feb 2025]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 15 Feb 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

HIV/AIDS

Uncertainty around PEPFAR programme puts millions of people at risk

Press Release 13 Feb 2025

- MSF is witnessing the impacts of the US government's decision to freeze funding to PEPFAR in countries where we work.
- While clarification on the decision was issued on 6 February, we remain concerned that key areas of HIV prevention are not included in this additional guidance.

Gaza-Israel war

Four questions about the situation in north Gaza

Interview 12 Feb 2025

National Academy of Medicine - USA [to 15 Feb 2025]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 15 Feb 2025]

<https://www.nationalacademies.org/newsroom>

News

No new digest content identified.

NIH [to 15 Feb 2025]

<http://www.nih.gov/>

News Releases

NIH-funded clinical trial will evaluate new dengue therapeutic

February 11, 2025 — Dengue virus sickens as many as 400 million people each year, primarily in tropical and subtropical parts of the world.

Single dose of broadly neutralizing antibody protects macaques from H5N1 influenza

February 11, 2025 — NIH science lays groundwork for future studies in people.

PATH [to 15 Feb 2025]

<https://www.path.org/media-center/>

Newsroom

PATH announces workforce reductions

February 13, 2025 by PATH

Last week, PATH leadership made the difficult decision to reduce our workforce. This decision comes in response to the unexpected pause in US government funding, which accounts for just over 30 percent of PATH's annual budget.

This was not a choice made lightly. PATH's people are our greatest asset. Our global team includes immensely dedicated and talented scientists, public health experts, engineers, advocates, and more—all working together to improve health and well-being for the people who need it most.

Though heartbreaking, these workforce reductions safeguard our ability to continue other critical health projects and ensure PATH can continue to support communities at the heart of our work.

The pause in US funding is a significant obstacle in global efforts to advance human health, but our commitment to the communities we serve remains steadfast. And our work continues—strong, focused, and driven by the urgency of the challenges ahead. Now, more than ever, we stand firm in our mission to transform global health and save lives.

Sabin Vaccine Institute [to 15 Feb 2025]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 15 Feb 2025]

<http://www.unaids.org/en>

News, Stories, Updates

Press release

UNAIDS rallies faith leaders in support of the HIV response at the Vatican in Rome

ROME/GENEVA, 13 February 2025—Today, the Executive Director of UNAIDS Winnie Byanyima met with leaders in the Catholic Church as part of a global effort to mobilize voices of faith to stand up in a moment of crisis for the AIDS response.

Press statement

UNAIDS urges countries to invest in HIV prevention as key to ending AIDS

Despite proven effectiveness, UNAIDS is alarmed by a decrease in condom use in several countries

Geneva, 13 February 2025– On International Condom Day, UNAIDS and partners are calling for HIV prevention efforts to be stepped up. In 2023, around 3,500 people became newly infected with HIV every day, bringing the total number of people newly infected in 2023 to 1.3 million.

One of the most effective, low-cost HIV prevention tools available today are condoms which are 98% effective when used correctly and consistently. Condom use has averted an estimated 117 million new HIV infections globally from 1990 to 2019 however, new data reveal that there has been a decline of 6-15% in condom use in a number of countries, according to the Demographic and Health Surveys (DHS), a Condom Landscape Analysis, and the World Health Organization (WHO.)

UNICEF [to 15 Feb 2025]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Statement 13 February 2025

Children in eastern Democratic Republic of the Congo increasingly exposed to sexual violence, abduction and recruitment – UNICEF

KINSHASA/NEW YORK, 13 February 2025 – “I am deeply alarmed by the intensifying violence in the eastern Democratic Republic of the Congo and its impact on children and families. In North and South Kivu provinces, we are receiving horrific reports of grave violations against children by parties to the conflict, incl...

Unitaid [to 15 Feb 2025]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 15 Feb 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 15 Feb 2025]

<https://www.vaccineacceptance.org/>

No new digest content identified.

Vaccine Confidence Project [to 15 Feb 2025]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 15 Feb 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 15 Feb 2025]

<https://wellcome.org/news/all>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 15 Feb 2025]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 15 Feb 2025]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 15 Feb 2025]

<https://www.wfpha.org/>

Blog, Events

[18th world congress on public health – join the global movement for health equity](#)

Join the World Federation of Public Health Associations (WFPHA) and Public Health Association of South Africa (PHASA) in Cape Town, South Africa, on September 6-9, 2025, as we unite public health professionals to shape a healthier, more equitable future for all.

World Medical Association [WMA] [to 15 Feb 2025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [OIE] [to 15 Feb 2025]

<https://www.oie.int/>

Press Releases, Statements

No new digest content identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [to 15 Feb 2025]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 15 Feb 2025]

<https://www.bio.org/press-releases>

Press Releases

BIO Applauds Introduction of Bipartisan ORPHAN Cures Act

February 5, 2025

DCVMN – Developing Country Vaccine Manufacturers Network [to 15 Feb 2025]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 15 Feb 2025]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 15 Feb 2025]

<https://ifpma.org/>

News, Statements [Selected]

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 15 Feb 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 15 Feb 2025]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - *No new digest content identified.*

Bavarian Nordic

Latest News

February 14, 2025

Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News - No new digest announcements identified

BioNTech

Press Releases - No new digest announcements identified

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

15 February 2025

Penmenvy, GSK's 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY

:: Vaccine helps protect against five common disease-causing serogroups of *Neisseria meningitidis* (A, B, C, W and Y)

:: Broad serogroup coverage in one vaccine reduces injections to help improve vaccination rates and help protect more US adolescents and young adults

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases

Jan 13, 2025 Media article

[Novavax is Powering the Future of Vaccines Through R&D and Value-creating Business Strategy](#)

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases

February 13, 2025

[Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study](#)

:: Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasive E. coli disease

:: No safety signals related to the vaccine candidate were identified

Serum Institute

News & Announcements - No new digest announcements identified. -

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases

[Korea Begins Administration of Its First RSV Preventive Antibody Injection, 'Beyfortus®'](#)

SK-Sanofi launches RSV preventive antibody injection for all infants under 12 months.? RSV, a
majo...

2025.02.14

SK bioscience Collaborates with WHO to Strengthen Infectious Disease Response ... Demonstrates Technological Excellence Through SARS International Standard Material Research

-Collaborated with key global health authorities, including IVI, the U.S. FDA, and the U.K. MHRA-
2025.02.12

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

Home - [Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 2: E67-166 Feb 2025

<https://journalofethics.ama-assn.org/issue/pain-management-non-labor-and-delivery-obgyn-procedures>

Issue Theme: Pain Management in Non-Labor and Delivery OBGYN Procedures

American Journal of Human Genetics

Feb 06, 2025 Volume 112 Issue 2 p199-456

<https://www.cell.com/ajhg/current>

This month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Many tools developed for genome-wide analyses perform best in cohorts of a single ancestry group. The genomes of admixed populations contain segments from different ancestry groups and vary from person to person. These features present challenges to investigators who would like to expand the depth, breadth, and diversity of their studies. One approach to control for population structure in admixed populations is local ancestry interference (LAI). By assigning ancestry groups to discrete genomic regions, LAI can boost the power of multiple genomic analyses.

American Journal of Infection Control

February 2025 Volume 53 Issue 2 p175-284

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

February 2025 Volume 68 Issue 2 p217-428

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

February 2025 115(2)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 112 (2025): Issue 1 (Jan 2025)

<https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.112.issue-1.xml>

[Reviewed earlier]

Annals of Internal Medicine

January 2025 Volume 178, Issue 1

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 339 February 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/339/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 15 Feb 2025)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 15 Feb 2025)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 15 Feb 2025)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 15 Feb 2025)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 15 Feb 2025)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 15 Feb 2025)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 15 Feb 2025)

[No new digest content identified]

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 15 Feb 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

February 2025 - Volume 30 - 1
<https://ebm.bmj.com/content/30/1>
[Reviewed earlier]

BMJ Global Health

February 2025 - Volume 10 - 2
<https://gh.bmj.com/content/10/2>
Analysis

Seasonal influenza surveillance and vaccination policies in the WHO South-East Asian Region (12 February, 2025)

Saleh Haider, Md Zakiul Hassan

Original research

Impact of measles vaccination strategies on vaccination rates in low-income and middle-income countries: a systematic review and meta-analysis (10 February, 2025)

Kiddus Yitbarek, Abela Mahimbo, Firew Tekle Bobo, Mirkuzie Woldie, Meru Sheel, Jane Frawley, Andrew Hayen

Evaluation of oral cholera vaccine (Euvichol-Plus) effectiveness against *Vibrio cholerae* in Bangladesh: an interim analysis

(3 February, 2025)

Farhana Khanam, Md. Taufiqul Islam, Faisal Ahmmed, Md Nazmul Hasan Rajib, Md Ismail Hossen, Fahima Chowdhury, Ashraful Islam Khan, Md. Taufiqur Rahman Bhuiyan, Shahinur Haque, Prasanta Kumar Biswas, Amirul Islam Bhuiyan, Zahid Hasan Khan, Mohammad Ashraful Amin, Aninda Rahman, S M Shahriar Rizvi, Tahmina Shirin, Md Nazmul Islam, Amanda Tiffany, Lucy Breakwell, Firdausi Qadri, John D Clemens

Practice

Observational research in epidemic settings: a roadmap to reform (10 February, 2025)

Emily E Ricotta, Fausto A Bustos Carrillo, Samuel Angelli-Nichols, John Barugahare, Adia Benton, Colin J Carlson, Emma Chang-Rabley, Natalie E Dean, Stephany N Duda, Lisa Federer, Mary-Margaret A Fill, Elizabeth C LeRoy, Natalie M Linton, Marc Lipsitch, Maya B Mathur, Alexandra L Phelan, Annette Rid, Jennifer B Rosen, Lauren Sauer, Sheena G Sullivan, Mackenzie Zendt, Nicholas Evans

Responsible governance of genomics data and biospecimens in the context of broad consent: experiences of a pioneering access committee in Africa (8 February, 2025)

Ahmed Rebai, Akin Abayomi, P Andanda, R Kerr, Kobus Herbst, J Mabuka, R Wamuyu, Daima Bukini, C Dandara

Bulletin of the World Health Organization

Volume 103, Number 1, January 2025, 1-80
<https://www.who.int/publications/journals/bulletin/>

In this month's Bulletin

In the editorial section, Katherine Littler et al. (2) call for papers for a special theme issue on the ethics of research into health and climate change.

Gary Humphreys (5–6) reports on initiatives to mitigate unintended consequences of health policies. Glenda Gray talks to Humphreys (7–8) about her career working on HIV prevention and treatment.

[Reviewed earlier]

Cell

Feb 06, 2025 Volume 188 Issue 3 p573-868

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

Child Care, Health and Development

Volume 51, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 117, Issue 2 Pages: 311-598 February 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

February 2025 Volume 47 Issue 2 p115-178

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 22 Issue 1, February 2025

<https://journals.sagepub.com/toc/ctja/22/1>

[New issue; No digest content identified]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 15 Feb 2025]

[No new digest content identified]

Contemporary Clinical Trials

Volume 148 January 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/147/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 6 / December 2024

<https://www.liebertpub.com/toc/crispr/7/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 1 2025

<https://www.tandfonline.com/toc/icmo20/current>

[New issue; No digest content identified]

Current Opinion in Infectious Diseases

February 2025 - Volume 38 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 15 Feb 2025]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 4 Pages: 263-342 December 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

Development Policy Review

Volume 43, Issue 2 March 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[New issue; No digest content identified]

Disasters

Volume 49, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>

[Reviewed earlier]

EMBO Reports

Volume 26 Issue 2 27 January 2025
<https://www.embopress.org/toc/14693178/current>
[Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 1—January 2025
<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 49 December 2024
<https://www.sciencedirect.com/journal/epidemics/vol/49/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>
[Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 1 Pages: 1-45 January–February 2025
<https://onlinelibrary.wiley.com/toc/25782363/current>
Moral distress in clinical research • Research with incarcerated and homeless women
[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 3 - Fall 2024
<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>
[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024
<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>
[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 6, December 2024
<https://academic.oup.com/eurpub/issue/34/6>
[Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1
<https://www.tandfonline.com/toc/ierv20/current>
[Reviewed earlier]

Foreign Affairs

January/February 2025

<https://www.foreignaffairs.com/issues/2025/104/1>

Special Section

Will Trump Change the World?

Forum for Development Studies

Volume 51, 2024 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>

[Accessed 15 Feb 2025]

[No new digest content identified]

Gene Therapy – Nature

Volume 32 Issue 1, January 2025

<https://www.nature.com/gt/volumes/32/issues/1>

[Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 2 February 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/2>

[New issue; No digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 15 Feb 2025]

[No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>
https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc
[Accessed 15 Feb 2025]
[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025)
<http://www.tandfonline.com/toc/rgph20/current>
[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>
[Accessed 15 Feb 2025]
[No new digest content identified]

Health and Human Rights

Volume 26, Issue 2, December 2024
<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>
Special Section: Distress Migration and the Right to Health
[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 4 - October 2024
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>
[Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 1, January 2025
<https://academic.oup.com/heapol/issue/40/1>
[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>
[Accessed 15 Feb 2025]
[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 3-4 / February 2025
<https://www.liebertpub.com/toc/hum/36/3-4>
[New issue; No digest content identified]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

The US administration assault on DEIA is an assault on the humanitarian principles of humanity and impartiality

Article

February 12, 2025

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

Feb 11, 2025 Volume 58 Issue 2 p265-514

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 15 Feb 2025]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 15 Feb 2025]

[No new digest content identified]

International Health

Volume 17, Issue 1, January 2025

<https://academic.oup.com/inthealth/issue/17/1>

[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 2 (Dec 2024)

<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 1 (2025): January 2025

<https://brill.com/view/journals/chil/32/4/chil.32.issue-4.xml>

[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 6, December 2024

<https://academic.oup.com/ije/issue/53/6>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 4 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>

Table of contents

[Reviewed earlier]

JAMA

February 11, 2025, Vol 333, No. 6, Pages 445-547

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Health Forum

January 2025, Vol 6, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

January 2025, Vol 179, No. 1, Pages 3-108

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JB1 Evidence Synthesis

January 2025 - Volume 23 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

March 2025 Volume 76 Issue 3 p341-526

<https://www.jahonline.org/current>

[New issue; No digest content identified]

Journal of Artificial Intelligence Research

Vol. 81 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 6 December 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[New issue; No digest content identified]

Journal of Development Economics

Volume 172 January 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/172/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

March 2025 - Volume 79 - 3

<https://jech.bmj.com/content/79/3>

Original research

[Public health unit funding per capita and seasonal influenza vaccination among youth and adults in Ontario, Canada in 2013/2014 and 2018/2019](#) (21 October, 2024)

Jo Lin Chew, Brendan T Smith, Sarah A Buchan, Ambikaipakan Senthilselvan, Roman Pabayo

Journal of Evidence-Based Medicine

Volume 18, Issue 1 March 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[New issue; No digest content identified]

Journal of Global Ethics

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

Special Issue: 20th Anniversary Forum

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 1, February 2025

<https://muse.jhu.edu/issue/54278>

Table of Contents

[New issue; No digest content identified]

Journal of Immigrant and Minority Health

Volume 27, Issue 1 February 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-1>

Original Paper

SARS-CoV-2 Prevalence in a Delivering Refugee Population: Refugee Status, Payor Type, Race, and Vaccination Status

Eleanor U. Johnston, et al.

Open access 06 December 2024 Pages: 104 - 111

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 37, Issue 1 Pages: 1-349 January 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

February 2025 - Volume 51 - 2

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 275 December 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/275/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

January/February 2025 - Volume 31 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 4, December 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-4>

[Reviewed earlier]

Journal of the Royal Society – Interface

February 2025 Volume 22 Issue 223

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 1, January 2025

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 98 Number 12 December 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Feb 15, 2025 Volume 405 Number 10478 p517-596

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

Philanthropy for health: past, present, and future

The Lancet

Comment

Malaria vaccine introduction in Africa: progress and challenges

Benido Impouma, Amani Adidja, Franck Mboussou, Joseph Cabore, Matshidiso Moeti

In 2024, Africa reached a pivotal milestone in its decades-long fight against malaria, a disease that has caused 94% of global cases and 95% of related deaths in Africa.¹ Although global malaria mortality has substantially declined since 2000, the 2024 World Malaria Report² revealed a concerning trend: the global malaria incidence rate was 58·6 cases per 1000 people at risk in 2023, indicating that progress towards the WHO Global Technical Strategy target of 21·3 cases per 1000³ is off track. This is particularly concerning for the African Region, which bears a disproportionate malaria burden. In this challenging landscape, the roll-out of malaria vaccines RTS,S/AS01 and R21/Matrix-M marked a transformative step in malaria elimination efforts.⁴ We discuss here the first year of malaria vaccine implementation, examining achievements, challenges, and strategic opportunities.

Offline: Telling the truth about WHO

Richard Horton

Articles

Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu, Democratic Republic of the Congo: a prospective cohort study

Isabel Brosius, et al.

The Lancet Child & Adolescent Health

Feb 2025 Volume 9 Number 2 p77-150, e1-e3

<https://www.thelancet.com/journals/lanchi/issue/current>

Editorial

A toolbox for innovative paediatric research

The Lancet Child & Adolescent Health

Health Policy

Building global collaborative research networks in paediatric critical care: a roadmap

Luregn J Schlapbach, et al. on behalf of the Australian and New Zealand Intensive Care Society Paediatric Study Group, Brazilian Research Network in Pediatric Intensive Care, Canadian Critical Care Trials Group, European Society of Paediatric and Neonatal Intensive Care, Pediatric Collaborative Network of Latin America, Pediatric Acute & Critical Care Medicine Asian Network, Pediatric Acute Lung Injury and Sepsis Investigators, United Kingdom Paediatric Critical Care Society Study Group, Pediatric Intensive Care Latin-American Society, World Federation of Pediatric Intensive & Critical Care Societies

Summary

Paediatric critical care units are designed for children at a vulnerable stage of development, yet the evidence base for practice and policy in paediatric critical care remains scarce. In this Health Policy, we present a roadmap providing strategic guidance for international paediatric critical care trials. We convened a multidisciplinary group of 32 paediatric critical care experts from six continents representing paediatric critical care research networks and groups. The group identified key challenges to paediatric critical care research, including lower patient numbers than for adult critical care, heterogeneity related to cognitive development, comorbidities and illness or injury, consent challenges, disproportionately little research funding for paediatric critical care, and poor infrastructure in resource-limited settings. A seven-point roadmap was proposed: (1) formation of an international paediatric critical care research network; (2) development of a web-based toolkit library to support paediatric critical care trials; (3) establishment of a global paediatric critical care trial repository, including systematic prioritisation of topics and populations for interventional trials; (4) development of a harmonised trial minimum set of trial data elements and data dictionary; (5) building of infrastructure and capability to support platform trials; (6) funder advocacy; and (7) development of a collaborative implementation programme. Implementation of this roadmap will contribute to the successful design and conduct of trials that match the needs of globally diverse paediatric populations.

Lancet Digital Health

Feb 2025 Volume 7 Number 2 e103-e166

<https://www.thelancet.com/journals/landig/issue/current>

Viewpoint

The urgent need to accelerate synthetic data privacy frameworks for medical research

Anmol Arora, et al.

Summary

Synthetic data, generated through artificial intelligence technologies such as generative adversarial networks and latent diffusion models, maintain aggregate patterns and relationships present in the real data the technologies were trained on without exposing individual identities, thereby mitigating re-identification risks. This approach has been gaining traction in biomedical research because of its ability to preserve privacy and enable dataset sharing between organisations. Although the use of synthetic data has become widespread in other domains, such as finance and high-energy physics, use in medical research raises novel issues. The use of synthetic data as a method of preserving the privacy of data used to train models requires that the data are high fidelity with the original data to preserve utility, but must be sufficiently different as to protect against adversarial or accidental re-identification. There is a need for the development of standards for synthetic data generation and consensus

standards for its evaluation. As synthetic data applications expand, ongoing legal and ethical evaluations are crucial to ensure that they remain a secure and effective tool for advancing medical research without compromising individual privacy.

[From the 100 Day Mission to 100 lines of software development: how to improve early outbreak analytics](#)

Carmen Tamayo Cuartero, et al.

Lancet Global Health

Feb 2025 Volume 13 Number 2 e172-e371

<https://www.thelancet.com/journals/langlo/issue/current>

Comment

[Harnessing the power of multicountry networks for influenza vaccine monitoring](#)

Cecile Viboud, Kathleen M Neuzil

Articles

[Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design](#)

Radhika Gharpure, et al.

[Emergence and spread of the SARS-CoV-2 omicron \(BA.1\) variant across Africa: an observational study](#)

Carlo Fischer, et al.

[Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9–14 years: results of the long-term extension of the DoRIS randomised trial](#)

Deborah Watson-Jones, et al.

Lancet Infectious Diseases

Feb 2025 Volume 25 Number 2 p135-242, e60-e113

<https://www.thelancet.com/journals/laninf/issue/current>

Editorial

[Vaccination in Africa—no hesitancy without access](#)

The Lancet Infectious Diseases

Articles

[Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial](#)

Amparo L Figueroa,

[Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial](#)

Matthijs P Raadsen, et al. for the MVA-MERS-S_DF-1 Study group

Personal View

[Sustainable antimicrobial resistance surveillance: time for a global funding mechanism](#)

Chris Painter, et al.

Lancet Public Health

Feb 2025 Volume 10 Number 2 e71-e164

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

Lancet Respiratory Medicine

Feb 2025 Volume 13 Number 2 p101-188, e9-e16

<https://www.thelancet.com/journals/lanres/issue/current>

Editorial

[**Respiratory research funding: consequences of neglect**](#)

The Lancet Respiratory Medicine

Maternal and Child Health Journal

Volume 28, Issue 12 December 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 1, January 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 4 Pages: 823-1031 December 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Feb 05, 2025 Volume 33 Issue 2 p423-824

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

Nature

Volume 638 Issue 8050, 13 February 2025

<https://www.nature.com/nature/volumes/637/issues/8049>

Review Article 12 Feb 2025

[**The neuroimmune connectome in health and disease**](#)

A review of studies on communication between the nervous and immune systems redefines the neuroimmune connectome with a focus on health and disease, and discusses how the latest techniques can advance our understanding.

Michael A. Wheeler, Francisco J. Quintana

Nature Biotechnology

Volume 43 Issue 2, February 2025
<https://www.nature.com/nbt/volumes/43/issues/2>
[New issue; No digest content identified]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 15 Feb 2025)
[Reviewed earlier]

Nature Genetics

Volume 57 Issue 2, February 2025
<https://www.nature.com/ng/volumes/57/issues/2>
Comment 03 Feb 2025

Introducing the Global Alliance for Spatial Technologies (GESTALT)

This Comment outlines the creation of the Global Alliance for Spatial Technologies (GESTALT), a collaborative initiative aimed at fostering the growth and standardization of spatial tissue profiling technologies. It explores the need for GESTALT, its community-driven structure and its goals, spanning from the immediate to the long term.

Jasmine T. Plummer, Ioannis S. Vlachos, Luciano G. Martelotto

Perspective 22 Jan 2025

Overcoming challenges associated with broad sharing of human genomic data

This Perspective discusses the definitions of 'broad' that have been used in the context of sharing of human genomic data and proposes a clarified and reformed terminology for describing genomic data sharing more precisely.

Jonathan E. LoTempio Jr, Jonathan D. Moreno

Nature Human Behaviour

Volume 9 Issue 1, January 2025
<https://www.nature.com/nathumbehav/volumes/9/issues/1>
[Reviewed earlier]

Nature Medicine

Volume 31 Issue 1, January 2025
<https://www.nature.com/nm/volumes/31/issues/1>
[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 1, January 2025
<https://www.nature.com/nrd/volumes/24/issues/1>
[Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 2, February 2025
<https://www.nature.com/nrg/volumes/26/issues/2>
Comment 18 Oct 2024

Ethical governance for genomic data science in the cloud

Rahimzadeh et al. discuss the ethical, legal and social implications of storing and analysing human genomic data in the cloud and provide recommendations and new research directions for future, trustworthy cloud-based genomic data access and management.
Vasiliki Rahimzadeh, Sarah C. Nelson, Stephanie M. Fullerton

Reviews

Progress in toxicogenomics to protect human health

Toxicogenomics leverages molecular data to predict toxicological effects. In this Review, the authors summarize innovations in transcriptomics and emerging methods, such as single-cell technologies and multi-omics, that offer detailed insights into toxicological mechanisms to enhance hazard prediction and risk assessment.

Matthew J. Meier, Joshua Harrill, Carole L. Yauk

Review Article 02 Sept 2024

Genome-scale models in human metabologenomics

Metabologenomics integrates multi-omics data into genome-scale metabolic models (GEMs) to analyse complex metabolic networks. Mardinoglu and Palsson review advancements in GEMs at the global, cell- and tissue-specific, microbiome and whole-body levels, with insights into their applications towards improving health care.

Adil Mardinoglu, Bernhard Ø. Palsson

Roadmap 07 Oct 2024

A call to action to scale up research and clinical genomic data sharing

Global genomic data sharing enhances precision medicine. In this Roadmap, the authors outline evolving data-sharing models, best practices and policy impacts, and propose 12 actions to systematically scale up genomic data sharing.

Zornitza Stark, David Glazer, Richard H. Scott

Nature Reviews Immunology

Volume 25 Issue 1, January 2025

<https://www.nature.com/nri/volumes/25/issues/1>

[New issue; No digest content identified]

New England Journal of Medicine

Volume 392 No. 7 February 13, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

Perspective

Marburg Virus Disease in Rwanda — Centering Both Evidence and Equity

C.T. Nutt

Original Article

Evolving Epidemiology of Mpox in Africa in 2024

N. Ndemi and Others

NEJM Evidence

Volume 4 No. 2 February 2025

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
[Reviewed earlier]

npj Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 15 Feb 2025]

Article 12 Feb 2025

Identifying vaccine-hesitant subgroups in the Western Pacific using latent class analysis

Yongjin Choi, Kathy Leung, Leesa Lin

Pediatrics

Volume 155, Issue 2 February 2025

<https://publications.aap.org/pediatrics/issue/155/2>

[Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 3 March 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-3>

Original Research Article Open access 25 November 2024

Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States

Hiral Anil Shah, Ginita Jutlla, Zeki Kocaata

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 15 Feb 2025)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 15 Feb 2025)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 15 Feb 2025)

The African Medicines Agency - A potential gamechanger that requires strategic focus

Niteen Wairagkar, Benjamin Djoudalbaye, Inas Moubarak, Moustapha Zakari, Douglas N. Shaffer, Alex Juma Ismail, Dalia M.N. Abouhussein, Moji Christianah Adeyeye, Delese Mimi Darko, Adam Mitangu Fimbo, Richard T. Rukwata, Boitumelo Semete-Makokotlela, Emile Bienvenu, Julio Rakotonirina, Michele Sidibe, Jerome H. Kim, Minata Cessouma Samate, Nicaise Ndembu

Opinion | published 14 Feb 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004276>

International healthcare workers' experiences and perceptions of the 2022 multi-country mpox outbreak

Vanessa Apea, Boghuma K. Titanji, Francesca H. Dakin, Rosalie Hayes, Melanie Smuk, Habiba Kawu, Laura Waters, Itsik Levy, Daniel R. Kuritzkes, Monica Gandhi, Jürgen Rockstroh, Mauro Schechter, Martin Holt, Romain Palich, Claudia P. Cortes, Silvia Nozza, Cristina Mussini, Alexandra Calmy, Brenda E. Crabtree-Ramirez, José L. Blanco, Sanjay Bhagani, Claire Dewsnap, Chloe Orkin, On Behalf of the Mpox SHARE-NET Writing Group

Research Article | published 14 Feb 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003704>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 15 Feb 2025)

Protecting mother and baby: Learnings from an Ebola vaccination campaign on the evolving landscape of vaccines and pregnancy

Rebecca F. Grais, Kathleen M. Neuzil, Helen Rees, Cristiana M. Toscano

Perspective | published 11 Feb 2025 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004530>

Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data

Rosine Ingabire, Julien Nyombayire, Amelia Mazzei, Jean-Baptiste Mazarati, Jozef Noben, Michael Katwere, Rachel Parker, Sabin Nsanzimana, Kristin M. Wall, Tyronza Sharkey, Felix Sayinzoga, Amanda Tichacek, Niina Hammoud, Ellen Martinson, Ben Magod, Susan Allen, Etienne Karita

Research Article | published 11 Feb 2025 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004508>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 15 Feb 2025)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 15 Feb 2025]

Impact of perceived factors of coronavirus infection on COVID-19 vaccine uptake among healthcare workers in Ghana—Evidence from a cross-sectional analysis

Emmanuel K. Gelyi, John Azaare, Nana Koba Bonso, Mary Rachael Kpordoxah, Gifty Apiung Aninanya

Research Article | published 12 Feb 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0318662>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 15 Feb 2025]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

February 18, 2025 | vol. 122 | no. 7

<https://www.pnas.org/toc/pnas/122/7>

[New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 1, January 2025

<https://academic.oup.com/pnasnexus/issue/4/1>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 6 - December 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

Preventive Medicine

Volume 191 February 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/191/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

February 2025 Volume 292 Issue 2040

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 238 Pages 1-316 (January 2025)

<https://www.sciencedirect.com/journal/public-health/vol/238/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 17, Issue 3, November 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

Public Health Reports

Volume 140 Issue 1, January/February 2025

<https://journals.sagepub.com/toc/phrg/140/1>

Public Health Evaluation

Research article First published July 26, 2024

Effect of Childcare Influenza Vaccine Requirement on Vaccination Rates, New York City, 2012-2020

Amy E. Metroka DrPH

Research Article First published June 4, 2024

Cost-Effectiveness Analysis of Routine Outreach and Catch-Up Campaign Strategies for Measles, Mumps, and Rubella Vaccination in Chuuk, Federated States of Micronesia

Mehreen Meghani MPH

Qualitative Health Research

Volume 35 Issue 2, February 2025

<https://journals.sagepub.com/toc/QHR/current>

[New issue; No digest content identified]

Research Ethics

Volume 21 Issue 1, January 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 15 Feb 2025]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

11 Feb 2025

Opportunities for promoting open data in the Caribbean through biobanks

Special report | English

Risk Analysis

Volume 45, Issue 2 pages: 265-472 February 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 15 Feb 2025]

[No new digest content identified]

Royal Society Open Science

February 2025 Volume 12 Issue 2

<https://royalsocietypublishing.org/toc/rsos/current>
[New issue; No digest content identified]

Science

Volume 387| Issue 6735| 14 Feb 2025
<https://www.science.org/toc/science/current>
Editorial

Breaking the silence

BY H. Holden Thorp, Meagan Phelan
13 Feb 2025

[Excerpt]

... In the tense political environment for science around the world, authors and journals also will be called upon to defend scientific consensus on matters that have been considered closed for decades, such as whether vaccines cause autism, whether humans are causing climate change, and whether HIV causes AIDS. Attacking individual studies is a common tactic to undermine entire fields. The scientific community can respond effectively only if the public believes that when there is a problem, it will be quickly corrected. As difficult and scary as it is to talk to tough reporters and critics, the alternative can be far worse.

In Depth

U.S. aid freeze deals 'tectonic' blow to research

BY Catherine Offord, Jon Cohen, Martin Enserink
13 Feb 2025: 704-705

Scientists decry ethical violations as trials worldwide are paused and workers laid off

Science and Engineering Ethics

Volume 31, Issue 1 February 2025
<https://link.springer.com/journal/11948/volumes-and-issues/31-1>
[Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 785| 12 Feb 2025
<https://www.science.org/toc/stm/current>
[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>
[Accessed 15 Feb 2025]
[No new digest content identified]

Social Science & Medicine

Volume 364 January 2025
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/364/suppl/C>
[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 15 Feb 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 6 December 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-6>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 63 January–February 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/63/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 2 Pages: i-iv, 71-142 February 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

Vaccine

Volume 47 15 February 2025

<https://www.sciencedirect.com/journal/vaccine/vol/47/suppl/C>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 15 Feb 2025]

Open Access Review

[Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines](#)

by Dang-Khoa Vo and Kieu The Loan Trinh

Vaccines 2025, 13(2), 191; <https://doi.org/10.3390/vaccines13020191> (registering DOI) - 15 Feb 2025

Abstract

Using plants as bioreactors, molecular farming has emerged as a versatile and sustainable platform for producing recombinant vaccines, therapeutic proteins, industrial enzymes, and nutraceuticals. This innovative approach leverages the unique advantages of plants, including scalability, cost-effectiveness, and reduced risk of contamination with human

Open Access Systematic Review

[Prevalence of Mpox Vaccine Acceptance Among Students: A Systematic Review and Meta-Analysis](#)

by Ambanna Yappalparvi, Shilpa Gaidhane, G. Padmapriya, Irwanjot Kaur, Madan Lal, Suhaib Iqbal, G. V. Siva Prasad, Atreyi Pramanik, Promila Sharma, Praveen Malik, Teena Vishwakarma, Ankit Punia, Megha Jagga, Rachana Mehta, Sanjit Sah, Muhammed Shabil, Prakasini Satapathy, Ganesh Bushi, Ali Davod Parsa and Russell Kabir

Vaccines 2025, 13(2), 183; <https://doi.org/10.3390/vaccines13020183> - 13 Feb 2025

Abstract

Background: Mpox, formerly known as monkeypox, is a re-emerging viral disease. Vaccine acceptance is crucial for preventing its spread. This systematic review and meta-analysis assessed the acceptance of the Mpox vaccine among student populations. Methods: We searched electronic databases, including PubMed, Web of [..

Open Access Review

Invasive Meningococcal Disease in the Post-COVID World: Patterns of Disease Rebound

by Jamie Findlow, Myint Tin Tin Htar, Rodolfo Villena and Paul Balmer

Vaccines 2025, 13(2), 165; <https://doi.org/10.3390/vaccines13020165> - 8 Feb 2025

Abstract

Invasive meningococcal disease (IMD) is a global health threat with an unpredictable epidemiology that varies regionally and over time. During the COVID-19 pandemic, the Invasive Respiratory Infection Surveillance Consortium reported widespread reductions in bacterial diseases transmitted via the respiratory route, including IMD, that [...

Value in Health

February 2025 Volume 28 Issue 2 p175-322

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 186 February 2025

<https://www.sciencedirect.com/journal/world-development/vol/186/suppl/C>

Research article Abstract only

What do aid recipients want? Public attitudes toward foreign aid in developing countries

Sung Eun Kim, Jong Hee Park, Inbok Rhee, Joonseok Yang

Article 106815

Research article Abstract only

Conceptualizing and evaluating how international organizations collaborate

Tamar Gutner, Rasmus Heltberg

Article 106789

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 15 Feb 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

[arXiv:2502.07794](https://arxiv.org/abs/2502.07794) [pdf, other]

Regulatory Science Innovation for Generative AI and Large Language Models in Health and Medicine: A Global Call for Action

Jasmine Chiat Ling Ong, Yilin Ning, Mingxuan Liu, Yian Ma, Zhao Liang, Kuldev Singh, Robert T Chang, Silke Vogel, John CW Lim, Iris Siu Kwan Tan, Oscar Freyer, Stephen Gilbert, Danielle S Bitterman, Xiaoxuan Liu, Alastair K Denniston, Nan Liu

The integration of generative AI (GenAI) and large language models (LLMs) in healthcare presents both unprecedented opportunities and challenges, necessitating innovative regulatory approaches. GenAI and LLMs offer broad applications, from automating clinical workflows to personalizing diagnostics. However, the non-deterministic outputs, broad functionalities and complex integration of GenAI and LLMs challenge existing medical device regulatory frameworks, including the total product life cycle (TPLC) approach. Here we discuss the constraints of the TPLC approach to GenAI and LLM-based medical device regulation, and advocate for global collaboration in regulatory science research. This serves as the foundation for developing innovative approaches including adaptive policies and regulatory sandboxes, to test and refine governance in real-world settings. International harmonization, as seen with the International Medical Device Regulators Forum, is essential to manage implications of LLM on global health, including risks of widening health inequities driven by inherent model biases. By engaging multidisciplinary expertise, prioritizing iterative, data-driven approaches, and focusing on the needs of diverse populations, global regulatory science research enables the responsible and equitable advancement of LLM innovations in healthcare.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 15 Feb 2025]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 15 Feb 2025]

[Filter: All articles]

MMR vaccination coverage in the U.S. before and after the COVID-19 pandemic: A modelling study

Ensheng Dong, Andreas Nearchou, Yamato Okura, Samee Saiyed, Lauren Marie Gardner

medRxiv 2025.02.13.25322239; doi: <https://doi.org/10.1101/2025.02.13.25322239>

Exploration of the Social Determinants of Diarrhoea, Rotavirus Vaccine Uptake, and Vaccine 'Fatigue' in Ethiopia, Kenya, and Malawi

Mackwellings Phiri, Rahma Osman, Shewit Weldegebriel, Steven Sabola, Beatrice Ongadi, Catherine Beavis, Chikondi Mwendera, Deborah Nyirenda, GHRG-GI Consortium

medRxiv 2025.02.07.25321869; doi: <https://doi.org/10.1101/2025.02.07.25321869>

Leveraging Large-Scale Biobanks for Therapeutic Target Discovery

Brian R Ferolito, Hesam Dashti, Claudia Giambartolomei, Gina M Peloso, Daniel J Golden, Kai Gravel-Pucillo, Danielle Rasooly, Andrea RVR Horimoto, Rachael Matty, Liam Gaziano, Yi Liu, Ines A Smit, Barbara Zdrazil, Yakov Tsepilov, Lauren Costa, Nicole Kosik, Jennifer E Huffman, Gian Gaetano Tartaglia, Giorgio Bini, Gabriele Proietti, Harris Ioannidis, Fiona Hunter, Gibran Hemani, Adam S Butterworth, Emanuele Di Angelantonio, Claudia Langenberg, Maya Ghoussaini, Andrew R Leach,

Katherine P Liao, Scott Damrauer, Luis E Selva, Stacey Whitbourne, Philip S Tsao, Jennifer Moser, Tom Gaunt, Tianxi Cai, John C Whittaker, Million Veteran Program, Juan P Casas, Sumitra Muralidhar, J Michael Gaziano, Kelly Cho, Alexandre C Pereira
medRxiv 2025.02.10.25321487; doi: <https://doi.org/10.1101/2025.02.10.25321487>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 15 Feb 2025]

Systematic Review Open Access

[Scoping review of knowledge graph applications in biomedical and healthcare sciences](#)

[version 1; peer review: awaiting peer review]

Sanjay Budhdeo, et al.

Abstract

Introduction

There is increasing use of knowledge graphs within medicine and healthcare, but a comprehensive survey of their applications in biomedical and healthcare sciences is lacking. Our primary aim is to systematically describe knowledge graph use cases, data characteristics, and research attributes in the academic literature. Our secondary objective is to assess the extent of real-world validation of findings from knowledge graph analysis.

* * * *

Think Tanks

Brookings [to 15 Feb 2025]

<http://www.brookings.edu/>

Reports, Events

No new digest content identified.

Center for Global Development [to 15 Feb 2025]

<https://www.cgdev.org/>

All Research

CGD NOTES

[A New Compact for Health Financing: Insights from Policymakers Across Africa](#)

[Anastassia Demeshko](#) et al.

February 07, 2025

The political economy of global health financing is increasingly driven by fiscal constraints, geopolitical instability, and shifting power dynamics. The COVID-19 pandemic stalled or reversed health gains, and countries and donors now face tightening budgets and rising debt repayments, threatening t...

WORKING PAPERS

It's All Fun and Games? The Persistent Treatment Effects of Willingness-to-Pay Experiments

Jenny C. Aker et al.

February 05, 2025

Willingness-to-pay (WTP) experiments have been widely used to assess demand for a variety of products. Do they also generate persistent treatment effects? We answer this question using a randomized controlled trial of a baseline WTP experiment, combined with in-person and phone survey data over a fo...

Chatham House [to 15 Feb 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 15 Feb 2025]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 15 Feb 2025]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 15 Feb 2025]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 15 Feb 2025]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 15 Feb 2025]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 15 Feb 2025]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 15 Feb 2025]
<https://www.rand.org/pubs.html>
Published Research [Selected]
Research Feb 12, 2025

Incorporating Social Determinants of Health Into Agent-Based Models of HIV Transmission: Methodological Challenges and Future Directions

Reviews methods and challenges of incorporating social determinants into HIV transmission models.

Research Feb 12, 2025
Intersectional HIV Stigma in Sub-Saharan Africa, Latin America and the Caribbean: Insights and Pathways Forward – A Scoping Review

This review covers research on intersectional HIV stigma in Sub-Saharan Africa, Latin America, and the Caribbean.

Feb 10. 2025
Toward Comprehensive Benchmarking of the Biological Knowledge of Frontier Large Language Models

...In this working paper, the authors describe an early component of a wider research effort analyzing the extent to which malicious actors with broad scientific knowledge may be able to use large language models through increasingly capable AI systems to develop biological or chemical weapons, including through modified systems lacking safety measures. The authors evaluated 31 of the most-capable models, as of January 2025, against public knowledge benchmarks — standardized tests or datasets used to evaluate the performance of different AI models on a specific task — relevant to biological and chemical threats. They tested the biological and chemical knowledge of the most cutting-edge large language models, with and without safety guardrails and with increased exposure to biological information.

Urban Institute [to 15 Feb 2025]
<https://www.urban.org/publications>
New Research Publications - Selected

World Economic Forum [to 15 Feb 2025]
<https://agenda.weforum.org/press/>
Media [Selected]
No new digest content identified.

*	*	*	*
*	*	*	*

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*